<DOC>
	<DOCNO>NCT00864474</DOCNO>
	<brief_summary>The objective surveillance collect information 1 ) adverse drug reaction expect LPD ( unknown adverse drug reaction ) , 2 ) incidence adverse drug reaction surveillance , 3 ) factor consider affect safety and/or efficacy drug .</brief_summary>
	<brief_title>Safety And Efficacy Of Maraviroc In Patients For HIV Patients ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description>All patient investigator prescribes first CELSENTRI® Tablets register consecutively number subject reach target number order extract patient enrol investigation random .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Patients need administer CELSENTRI® Tablets order enrol surveillance . Patients administer CELSENTRI® Tablets .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>